Article Text

Download PDFPDF
Digital ischaemia and necrosis from oxaliplatin
  1. Charity Huang1,2,
  2. Leslie Storey3 and
  3. Uzair Chaudhary1,2
  1. 1Hematology Oncology, University of California San Francisco-Fresno, Fresno, California, USA
  2. 2Hematology Oncology, University of California San Francisco-Fresno, Clovis, California, USA
  3. 3Dermatology, University of California San Franciso-Fresno, Fresno, CA, USA
  1. Correspondence to Dr Charity Huang; Charity.Huang{at}UCSF.edu

Abstract

Oxaliplatin is a chemotherapeutic agent used in a variety of malignancies such as colorectal cancer and pancreatic cancer. It is a platinum derivative that results in direct cell cytotoxicity with resultant cell death. The most common side effects often noted are neurotoxicity, nausea, vomiting, diarrhoea, hepatotoxicity and myelosuppression. Oxaliplatin induced digital ischaemia and necrosis is a rare side effect that was observed in our patient. In general, digital ischaemia is a rare vascular disorder that is often associated with autoimmune disease. A patient with digital ischaemia due to oxaliplatin will be described in this case report.

  • chemotherapy
  • urological cancer
  • cancer intervention
  • contraindications and precautions
  • musculoskeletal and joint disorders

Statistics from Altmetric.com

Footnotes

  • Twitter @CharityHuangMD

  • Contributors CH - chart review, write up of case report, submission of case report. LS - participated in patient care, provided photo of patient’s fingertips. UC - participated in patient care and treatment decision making regarding complications, direct communication with family members regarding case report after patient’s death, editing of case report.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Case reports provide a valuable learning resource for the scientific community and can indicate areas of interest for future research. They should not be used in isolation to guide treatment choices or public health policy.

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.